The main objective of the Boston University Pilot and Feasibility (P&F) Program is to catalyze transformative advances in both translational and basic diabetes research, expanding and broadening the innovative parent Joslin P&F program. The new program would be integrated into the parent Joslin P&F program and will adopt its administrative and scientific policies and infrastructure. The program will have two main components: a regional Computational Systems Biology program and a Boston University Medical Center based new investigator program. The majority of the researchers enrolled in the new Computational Systems Biology program are either new or well-established systems biology researchers at BU, MIT or Harvard with limited prior research in diabetes or metabolic diseases. Thus, the scientific benefits from this program are expected to be high since these researchers bring a substantial prior track record in systems biology or network research successfully applied in other biomedical areas, but they have not previously worked in the biology, genetics or translational aspects of diabetes. The BU Medical Center program will emphasize funding new investigators who work in areas complementary to the focus areas of the Joslin primary P&F program and will include cardiovascular complications related to diabetes and obesity.
The new Pilot and Feasibility Grant Program at Boston University provides seed grants to attract new researchers to the diabetes field. It specifically funds 1. New investigators in the diabetes field who have not previously received substantial NIH funding;2. Experienced investigators in the diabetes field who wish to strike out in a novel direction;and 3. Investigators from other fields embarking on a diabetes-related project for the first time.
|Mezza, Teresa; Sorice, Gian P; Conte, Caterina et al. (2016) Î²-Cell Glucose Sensitivity Is Linked to Insulin/Glucagon Bihormonal Cells in Nondiabetic Humans. J Clin Endocrinol Metab 101:470-5|
|Shirakawa, J; Kulkarni, R N (2016) Novel factors modulating human Î²-cell proliferation. Diabetes Obes Metab 18 Suppl 1:71-7|
|Bonner-Weir, Susan; Aguayo-Mazzucato, Cristina (2016) Physiology: Pancreatic Î²-cell heterogeneity revisited. Nature 535:365-6|
|Hettmer, Simone; Lin, Michael M; Tchessalova, Daria et al. (2016) Hedgehog-driven myogenic tumors recapitulate skeletal muscle cellular heterogeneity. Exp Cell Res 340:43-52|
|Kokoye, Yasin; Ivanov, Ivan; Cheng, Qiufang et al. (2016) A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation. Thromb Res 140:118-24|
|Vegas, Arturo J; Veiseh, Omid; Doloff, Joshua C et al. (2016) Combinatorial hydrogel library enables identification of materials that mitigate the foreign body response in primates. Nat Biotechnol 34:345-52|
|Khamaisi, Mogher; Katagiri, Sayaka; Keenan, Hillary et al. (2016) PKCÎ´ inhibition normalizes the wound-healing capacity of diabetic human fibroblasts. J Clin Invest 126:837-53|
|Garvey, Katharine C; Telo, Gabriela H; Needleman, Joseph S et al. (2016) Health Care Transition in Young Adults With Type 1 Diabetes: Perspectives of Adult Endocrinologists in the U.S. Diabetes Care 39:190-7|
|Bonner-Weir, Susan; Aguayo-Mazzucato, Cristina; Weir, Gordon C (2016) Dynamic development of the pancreas from birth to adulthood. Ups J Med Sci 121:155-8|
|Ogawa, Takahiro; Kodera, Yukihiro; Hirata, Dai et al. (2016) Natural thioallyl compounds increase oxidative stress resistance and lifespan in Caenorhabditis elegans by modulating SKN-1/Nrf. Sci Rep 6:21611|
Showing the most recent 10 out of 933 publications